Cellmid: Signs agreement with Emergence Technology for SARS-CoV-2 tests
- Life sciences company, Cellmid (CDY) has signed a non-exclusive introducer agreement with Emergence Technology for SARS-CoV-2 tests
- The agreement will begin immediately and will allow Cellmid to introduce its customers to Emergence, who will supply the tests until the demand no longer needed
- The agreement with Wondfo will expire at the end of this month, however, this could extended if Wondfo provides written consent
- Emergence is currently in negotiations with Wondfo, the antibody test’s manufacturer, to distribute the test in Australia
- Scientific evidence has shown that using nucleotide and antibody tests together improves accuracy in diagnosing COVID-19
- Cellmid shares suspended, with last trade selling shares for 18.5¢ each on May 6